Given at higher doses than in diabetes treatment, GLP-1 analogues are now routinely licensed for the treatment of obesity, for example high-dose Liraglutide 3 mg daily (43) and Semaglutide 2.4 mg weekly (44). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.